Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
135
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

Mingyang Ren1 Department of Graduate School, Bengbu Medical College, Bengbu, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-4428-831XView further author information
ORCID Icon,
Xianhong Yang2 Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, People’s Republic of ChinaView further author information
,
Yan Teng2 Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3817-6696View further author information
ORCID Icon,
Wei Lu2 Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, People’s Republic of ChinaView further author information
,
Yang Ding2 Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0706-1124View further author information
ORCID Icon &
Xiaohua Tao2 Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3527-2914View further author information
ORCID Icon
Pages 3369-3374 | Received 13 Sep 2023, Accepted 11 Nov 2023, Published online: 20 Nov 2023

References

  • Uliandri J, Wang X, Liu Z, et al. Global rosacea treatment guidelines and expert consensus points: the differences. J Cosmet Dermatol. 2019;18(4):960–965.
  • Van Zuuren EJ, Arents BWM, van der Linden MMD, et al. Rosacea: new concepts in classification and treatment. Am J Clin Dermatol. 2021;22(4):457–465. doi:10.1007/s40257-021-00595-7
  • Jang YJ, Hong EH, Park EJ, et al. Immunohistochemical analysis of differences of toll-like receptor 2, mast cells, and neurofilaments between granulomatous rosacea and non-granulomatous rosacea. Indian J Dermatol. 2021;66(4):343–346. doi:10.4103/ijd.IJD_18_20
  • Mullanax MG, Kierland RR. Granulomatous rosacea. Arch Dermatol. 1970;101(2):206–211. doi:10.1001/archderm.1970.04000020076011
  • Slater N, Rapini RP. Lupus miliaris disseminatus faciei. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  • Lee GL, Zirwas MJ. Granulomatous rosacea and periorificial dermatitis: controversies and review of management and treatment. Dermatol Clin. 2015;33(3):447–455. doi:10.1016/j.det.2015.03.009
  • Lane JE, Khachemoune A. Use of intense pulsed light to treat refractory granulomatous rosacea. Dermatol Surg. 2010;36(4):571–573. doi:10.1111/j.1524-4725.2010.01503.x
  • Sun YH, Man XY, Xuan XY, et al. Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series. Dermatol Ther. 2022;35(11):e15848. doi:10.1111/dth.15848
  • Li T, Wang H, Wang C, et al. Tofacitinib for the treatment of steroid-induced rosacea. Clin Cosmet Investig Dermatol. 2022;15:2519–2521. doi:10.2147/CCID.S392280
  • Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi:10.1038/s41392-021-00791-1
  • Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. doi:10.1016/j.intimp.2020.106210
  • McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803–816. doi:10.1016/S0140-6736(21)00438-4
  • Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149–2157. doi:10.1007/s40265-021-01638-3
  • Li T, Zeng Q, Chen X, et al. The therapeutic effect of artesunate on rosacea through the inhibition of the JAK/STAT signaling pathway. Mol Med Rep. 2018;17(6):8385–8390. doi:10.3892/mmr.2018.8887
  • Kumari A, Srivastava A, Jagdale P, et al. Lambda-cyhalothrin enhances inflammation in nigrostriatal region in rats: regulatory role of NF-κβ and JAK-STAT signaling. Neurotoxicology. 2023;96:101–117. doi:10.1016/j.neuro.2023.04.003
  • Zhou J, Li T, Chen H, et al. ADAMTS10 inhibits aggressiveness via JAK/STAT/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer. Gastric Cancer. 2022;25(6):1002–1016. doi:10.1007/s10120-022-01319-4
  • Zhang Y, Li Y, Zhou L, et al. Nav1.8 in keratinocytes contributes to ROS-mediated inflammation in inflammatory skin diseases. Redox Biol. 2022;55:102427. doi:10.1016/j.redox.2022.102427
  • Shen S, Yan G, Cao Y, et al. Dietary supplementation of n-3 PUFAs ameliorates LL37-induced rosacea-like skin inflammation via inhibition of TLR2/MyD88/NF-κB pathway. Biomed Pharmacother. 2023;157:114091. doi:10.1016/j.biopha.2022.114091

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.